In December 2015, the Coalition government announced in its Mid-Year Economic and Fiscal Outlook (MYEFO) that it would remove bulk-billing incentive payments for pathology services, with projected savings of $650 million over four years [1].
The bulk-billing incentives being removed were payments of between $1.40 and $3.40 made directly to pathology service providers to encourage them to bulk-bill patients [2].
The government argued these incentives were being used to cross-subsidise other business costs for large companies (some owned by private equity firms) rather than their intended purpose [2].
The article accurately reports Health Minister Sussan Ley's confirmation that the government would proceed with the cuts despite election timing concerns [1].
缺失的脈絡
此 cǐ 說法 shuō fǎ 省略 shěng lüè 了 le 幾個 jǐ gè 重要 zhòng yào 的 de 背景 bèi jǐng 元素 yuán sù : :
The claim omits several important contextual elements:
**The incentives were introduced by Labor in 2009.** The bulk-billing incentives for pathology were originally introduced by the previous Labor government under Kevin Rudd in 2009 [1].
These were relatively recent additions to the Medicare system, not long-established entitlements.
**A deal was struck to offset the impact.** In May 2016, the government reached an agreement with Pathology Australia (the industry body representing major providers like Sonic Healthcare and Genea) to introduce rent reforms for Approved Collection Centres [3].
This deal was intended to help pathology providers absorb the cost of losing the bulk-billing incentives by ensuring they paid "fair market value" rents when co-located in GP buildings [2].
**The policy rationale.** Health Minister Sussan Ley stated the government was "acting in the interests of a sustainable health system" and that the incentives were not meant to subsidise large corporate providers' business costs [1].
The Grattan Institute also noted that with 99% of pathology tests already bulk-billed, there were questions about whether these incentives were still necessary [2].
**Uneven impact across providers.** Not all pathology providers were treated equally by the rent deal.
Catholic Health Australia and other not-for-profit providers argued the deal disproportionately assisted large corporate providers and would not be sufficient to offset cuts for smaller, regional, and rural providers [2].
The original source, **ABC News** (Australian Broadcasting Corporation), is Australia's national public broadcaster.
其特點 qí tè diǎn 包括 bāo kuò : :
It is:
- A mainstream, reputable news organization
- Funded by taxpayers but governed by an independent board with legislated editorial independence
- Generally regarded as having minimal partisan bias
- Subject to rigorous editorial standards and accountability mechanisms
The ABC article is factual reporting of the Health Minister's statements and the Opposition's response, not an opinion piece.
**Did Labor do something similar?**
Search conducted: "Labor government pathology bulk billing Medicare policy history"
Finding: **Labor actually introduced these incentives in the first place.** The bulk-billing incentives for pathology that the Coalition cut were originally introduced by the Rudd Labor government in 2009 [1].
* * * *
Additionally, the Labor government initiated a Medicare rebate freeze in 2013 (just before losing office), which was then continued by the Coalition government [4].
This pattern shows both parties have taken measures to constrain Medicare spending growth.
**Comparative context:**
While Labor positioned itself as the defender of bulk-billing during the 2016 election (pledging to reverse the cuts), they also had a history of Medicare cost containment measures.
While the claim accurately states that the Coalition cut $650 million in bulk billing incentives, the full story is more nuanced:
**The government's position:** The Coalition argued the incentives were being misused by large corporate pathology providers (some owned by private equity) to subsidise other business costs rather than ensuring affordable patient access [2].
With nearly 99% of pathology tests already bulk-billed [2], the government questioned whether the incentives were achieving their intended purpose.
**The industry's response:** Pathology Australia launched a major "Don't Kill Bulk Bill" campaign, collecting nearly 600,000 signatures [2].
They warned patients would face co-payments, potentially up to $30 per test [1].
**The compromise:** The government struck a deal with Pathology Australia to regulate rents for collection rooms, which would help providers (particularly large corporate ones) absorb the cuts [2][3].
**The political dimension:** The cuts were scheduled to take effect on July 1, 2016 - the day before the federal election [1].
* * * * 行業 xíng yè 回應 huí yīng : : * * * * Pathology Pathology Australia Australia 發起 fā qǐ 了 le 大規模 dà guī mó 的 de 「 「 不要 bú yào 扼殺 è shā 批量 pī liàng 計費 jì fèi 」 」 運動 yùn dòng , , 收集 shōu jí 了 le 近 jìn 60 60 萬個 wàn gè 簽名 qiān míng [ [ 2 2 ] ] 。 。
This timing made the issue highly politically charged, with Labor running a "Mediscare" campaign and the Coalition defending the policy as necessary for sustainability [2].
**Key context:** This was not a cut to fundamental Medicare benefits but the removal of incentive payments that had only existed since 2009.
Whether this represented a genuine threat to patient access or prudent fiscal management depended largely on which pathology provider a patient visited.
However, the claim presents this without critical context: (1) these incentives were only introduced by Labor in 2009, not long-standing entitlements; (2) the government struck a deal with Pathology Australia on rent reforms to offset the impact; (3) the policy was driven by concerns that large corporate providers were using incentives to subsidise business costs rather than patient care; and (4) with 99% bulk-billing rates, there were legitimate questions about whether these incentives were still necessary.
However, the claim presents this without critical context: (1) these incentives were only introduced by Labor in 2009, not long-standing entitlements; (2) the government struck a deal with Pathology Australia on rent reforms to offset the impact; (3) the policy was driven by concerns that large corporate providers were using incentives to subsidise business costs rather than patient care; and (4) with 99% bulk-billing rates, there were legitimate questions about whether these incentives were still necessary.